Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia at the 2025 ASH Meeting.
Marc S. Hoffmann, MD
Advertisement
Articles by Marc S. Hoffmann, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
4
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
5
